Skip to content
DataLookout
Menu

NCT07537634

Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication

StatusCompleted
PhasePhase 4
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 17 words Show 6 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Aug 14, 2026 to Sep 14, 2026
    • Study sites: 2 to 1
    • Secondary endpoints: details revised at 1 of 4 entries
    • Study description expanded, about 6 words
    • Publications: details revised at 1 of 2 entries
  2. Notable Recruitment opened
    • Study sites: 1 to 2
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

H. pylori Eradication Rate
Timeframe: 4 weeks after completion of 14-day therapy

Secondary (4)

Endoscopic Mucosal Healing rate
Change in dyspeptic symptom severity score
Adverse Events
Compliance to Therapy

Arms and interventions

Vonoprazan-based triple therapy (VAL)Experimental

Participants in this arms will receive vonoprazan based levofloxacin containing triple therapy for 14 days

Esomeprazole-based triple therapy (EAL)Active comparator

Participants in this arms will receive esomeprazole based levofloxacin containing triple therapy for 14 days

Drugs: vonoprazan-based triple therapy (VAL regimen), Esomeprazole-based triple therapy (EAL regimen)

Sites

1 site in 1 country

  • Bangabandhu Sheikh Mujib Medical UniversityDhaka, Bangladesh